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Abst rac t
Atopic dermatitis (AD) is secondary to genetic, immunological and microbiological disorders as well as epidermal 
barrier defects, which are the main targets of therapy. The disease proceeds with periodic exacerbations. Its devel-
opment and course are influenced by numerous environmental and individual factors. In recent decades, in indus-
trialized countries, there has been a threefold increase in the incidence of AD. There is also an increasing number of 
cases resistant to topical treatment. Effective treatment of AD should provide control of clinical symptoms, prevent 
exacerbations and improve the quality of life of patients. The multifactorial etiopathogenesis and various endotypes 
and phenotypes of AD justify the tendency to optimize and personalize the therapy. Currently, we recommend the 
use of dupilumab for the treatment of patients from 12 years of age with moderate and severe atopic dermatitis, 
who do not respond to topical treatment.
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Introduction
Atopic dermatitis (ICD-10 L20) is a chronic disease that 
affects mainly children (10–20%) and lasts until adulthood 
in about 1/5 of this group [1]. The prevalence of AD in adults 
has been estimated at 2.1–4.9% [2]. In adulthood, the dis-
ease appears for the first time in one of four adult patients 
suffering from AD [3]. 
In over 60% of cases, there is an increased risk of de-
veloping atopic symptoms from other organs. Atopic der-
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matitis is the first step in the atopic march, in the course 
of which the following may develop: food allergy (15%), al-
lergic rhinitis (34%) and bronchial asthma (20–35%). Very 
severe and persistent itching, hypersensitivity and visible 
skin inflammation and stigmatization significantly reduce 
the quality of life and are often the cause of anxiety, sleep 
disorders, absenteeism at school and work, social isolation 
and, consequently, depression, mental illness and even sui-
cidal thoughts. Children with AD are more likely to develop 
abdominal obesity and arterial hypertension [4, 5]. 
Skin diseases associated with atopic dermatitis include 
ichthyosis (ichthyosis vulgaris), infectious diseases such as 
impetigo and herpetic eczema (eczema herpeticum), and 
immune diseases: alopecia areata and vitiligo (vitiligo). 
White dandruff (pityriasis alba) and keratosis pilaris are 
common in patients with AD [6, 7].
Cutaneous lymphoma may develop in adults with se-
vere AD. Moreover, the relationship between AD and obesity, 
metabolic syndrome, cardiovascular diseases and osteopo-
rosis has been described [8, 9]. 
Biological drugs in atopic dermatitis
Modern treatment of AD involves two groups of me-
dicinal products: monoclonal bodies that act precisely to 
inhibit specific cytokines or their receptors, and agonists or 
antagonists of small molecules. Action of those latter is even 
broader. It is now known that, in addition to the defect in the 
epidermal barrier and disorders of the skin microbiota ho-
meostasis, AD is immunologically characterized by abnormal 
activity of the Th2 cellular system expressed by excessive 
activity of cytokines such as IL4, IL13, cytokines secreted by 
Th17, Th22, Th1 lymphocytes and cytokines derived directly 
from the damaged epidermis (IL33, TSLP, IL25) [10–12]. In-
volvement of the Th2 cellular system seems to be the leading 
and ethnically or pheno-/endotypically independent factor. 
Which means it affects every patient with AD [13–15]. Hence, 
targeting the treatment to suppress the Th2 cellular system 
seems perfectly justified. In 2017, the FDA and EMA approved 
the drug dupilumab, the first biological drug in AD for the 
treatment of its moderate and severe form.
Dupilumab
Dupilumab is a human IgG4 monoclonal antibody di-
rected against the alpha subunit of the IL-4 receptor (IL-
4Rα), thanks to which it blocks both IL-4 and IL-13. The 
current approval of the drug covers the treatment of mod-
erate to severe AD in patients aged 12 years and over. 
Efficacyofdupilumabtherapyinchildrenfrom 
6yearsofage,adolescentsandadults
The efficacy and safety of dupilumab as a monother-
apy or administered concomitantly with topical glucocor-
ticoids in adults were assessed in randomized, double-
blind, placebo-controlled phase 2b trials in 452 patients, 
trials LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2 in 1379 
adult AD patients, and 740 patients in the LIBERTY AD 
CHRONOS trial lasting up to 52 weeks [16–19]. The tri-
als enrolled patients with a prior inadequate response 
to topical medications with severe to moderate AD as 
assessed by Investigator’s Global Assessment (IGA) score 
≥ 3, eczema area and severity index (EASI), Eczema Area 
and Severity Index ≥ 16 and Body Surface Area (BSA) 
≥ 10%. Dupilumab significantly improved the objective 
and subjective symptoms of AD and quality of life in 
patients with moderate to severe AD. A reduction in the 
SCORAD and EASI-75 scores, as well as a reduction in the 
severity of pruritus, anxiety/depression and sleep disor-
ders have been observed in adults [16–21]. The drug is 
administered subcutaneously at the first dose of 600 mg, 
followed by the dose of 300 mg s.c. every 2 weeks.
In the group of young people over 12 years of age, 
251 patients with a mean age of 14.5 ±1.7 years were ran-
domized. Majority of these patients had other allergic 
diseases such as asthma, food allergy, and allergic rhini-
tis. Dupilumab significantly improved signs, symptoms 
and quality of life in adolescents with moderate to se-
vere AD, with an acceptable safety profile. Effectiveness 
of the drug administered every 2 weeks was definitely 
higher than every 4 weeks [22]. Results were obtained 
and evaluated after 16 weeks of treatment. The drug is 
administered subcutaneously at the dose of 200 mg in 
children weighing < 60 kg or 300 mg for body weight 
≥ 60 kg, every 2 weeks or 300 mg every 4 weeks.
Data are available from the phase III clinical trial of 
dupilumab treatment with concomitant topical GCSs 
treatment in children aged 6–11 years with severe AD, 
with inadequately controlled topical treatment [23]. 
Three hundred sixty seven children were enrolled in the 
16-week study. Dupilumab was effective and improved 
the quality of life of patients in this age group. Taking 
into account the effectiveness and side effects, the opti-
mal dose was 300 mg every 4 weeks for children weigh-
ing less than 30 kg and 200 mg every 2 weeks for chil-
dren weighing 30 kg or more [23]. Data from registries 
and descriptions of patients treated with dupilumab, in 
real life, apart from clinical trials, indicate comparable re-
sults to those obtained during clinical trials [24–29].
Adversereactionsduringdupilumabtherapy 
inchildrenfrom6yearsofage,adolescentsandadults
The most common adverse reaction observed in 
22.1% of dupilumab users in adult clinical trials are con-
junctivitis and blepharitis [30, 31]. In observations dur-
ing the use of the drug outside clinical trials, this com-
plication reaches the level of 38.2% [26]. The suggested 
treatment is the use of artificial tears, drops with tGCS 
(fluorometholone 0.1%), topical calcineurin inhibitors 
(tCI) applied to the eyelids in moderate cases, and eye 
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drops or ointments containing cyclosporin or tacrolimus 
in severe forms [31, 32].
Most cases of conjunctivitis are transient and can be 
successfully treated by continuing the therapy with du-
pilumab [29]. In terms of rates of infection, it was found 
that it was similar in adult patients receiving dupilumab 
and placebo. Dupilumab did not increase the risk of infec-
tion, nasopharyngitis, or upper respiratory tract infection, 
and the systemic use of anti-infective agents was lower 
in the dupilumab group. Fewer serious/severe bacterial 
infections and other non-herpetic skin infections were 
observed among patients using dupilumab [33]. Among 
the side effects with long-term use of dupilumab, para-
doxical erythema of the face, décolleté and neck, usually 
after 10–39 weeks of using dupilumab, has been reported 
[34, 35]. In the group of adolescents > 12 years of age 
treated with dupilumab, a higher percentage of conjunc-
tivitis and reactions at the injection site and lower rates 
of non-herpetic skin infections were observed [21]. Chil-
dren with severe AD, aged 6–11 treated with dupilumab 
presented more frequent conjunctivitis and injection site 
reactions than the placebo group [23]. More research is 
needed in the pediatric group.
Laboratorytests,monitoringduringdupilumab
therapy
According to the evaluation of the results of avail-
able clinical trials conducted in the adult group, there 
is no need for laboratory monitoring during dupilumab 
therapy [36]. However, before and during dupilumab 
therapy (after 16 weeks and then every 3 months), we 
suggest performing basic tests (complete blood count 
with smear, AST, ALT, creatinine, urea, CRP). Before start-
ing the therapy, we additionally recommend a pregnancy 
test in women of childbearing age, ECG and chest X-ray 
examinations (Table 1).
Data on long-term safety in children and adolescents 
are time-limited and the size of the pediatric group indi-
cates a need to extend the research in these age groups.
Safetyoflong-termdupilumabtherapyinchildren
from6yearsofage,adolescentsandadults
Long-term safety of up to 3 years of use of dupilum-
ab has been established for adults [37, 38]. In the group 
of children aged 12–17 years, safety data covers up to 
52 weeks of treatment with dupilumab [39]. In this group, 
as well as in the group of 6–11-year-olds there are currently 
no results of studies lasting more than 1 year [23, 39].
Dupilumabcombinedwithotherdrugsusedin
atopicdermatitis
Dupilumab should be combined with the daily use 
of emollients and, if necessary, may be combined with 
topical anti-inflammatory drugs [40]. 
Recommendation
The use of dupilumab is recommended in patients 
from 12 years of age with moderate to severe AD (EASI 
≥ 16, SCORAD ≥ 25) who do not respond to local treat-
ment. The duration of therapy depends on the resolution 
of the disease and the decision of the treating physician. 
Dupilumab may be self-administered subcutaneously by 
the patient or his caregivers at home (Table 2). 
If there is no improvement after 16 weeks of dupilum-
ab use (assessed as not achieving at least a 50% reduc-
tion in the EASI score), treatment with this drug should 
be discontinued.
Other biological drugs – monoclonal bodies  
in the treatment of atopic dermatitis
Randomized, double-blind, placebo-controlled clini-
cal trials are currently underway to evaluate the efficacy 
and safety of other biologics in adult patients with mild 
and severe AD. There are test results for monoclonal an-
tibodies such as: tralokinumab, lebrikizumab (anti-IL-13), 
Table 2. Dosage of dupilumab for subcutaneous 
administration to patients with atopic dermatitis 
Patients Initial dose Subsequent 
doses (every 
2 weeks)
Adolescents from 12 to 17 years:
Below 60 kg 400 mg (two s.c. injections 
a’ 200 mg)
200 mg
60 kg or more 600 mg (two s.c. injections 
a’ 300 mg)
300 mg
Adults 600 mg (two s.c. injections 
a’ 300 mg)
300 mg
Table 1. Diagnostic procedures before and during the 
treatment with dupilumab
Procedures before start of the therapy with dupilumab:
General health assessment based on the medical history
Assessment of symptoms intensity with the EASI score
Blood cell count with smear
clinical chemistry: creatinine, urea, CRP, transaminases  
(ALT, AST)
X-ray of the chest
ECG
Pregnancy test in women of childbearing potential
Procedures after 16 weeks of the therapy, and then every 
3 months (±7 days):
General health assessment based on the medical history
Assessment of symptoms intensity with the EASI score
Blood cell count with smear
Clinical chemistry: creatinine, urea, CRP, transaminases  
(ALT, AST)
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nemolizumab (anti-IL-31Rα), fezakinumab (anti-IL-22), 
etokimab (anti-IL-33) and tezepelumab (anti-TSLP).
Lebrikizumab
Lebrikizumab is an IL-13 binding monoclonal anti-
body. A randomized, placebo-controlled phase II clinical 
trial enrolled 209 adult patients with severe to moderate 
AD in whom topical glucocorticoids (tGCSs) were inef-
fective. The drug efficacy and safety were assessed after 
12 weeks. The drug was administered to patients at the 
dose of 125 mg every 4 weeks – subcutaneously, and at 
the same time the use of tGCSs was allowed. Lebriki-
zumab led to significant clinical improvement and was 
well tolerated [41].
Tralokinumab
Tralokinumab is an IL-13 binding monoclonal anti-
body. The results of the phase 2b clinical trial were pub-
lished in 2019. The study included 204 adult patients 
with moderate and severe AD. The treatment was com-
bined with tGCSs. Results summarized after 12 weeks of 
therapy indicated that the treatment with tralocanumab 
was associated with an early and sustained improve-
ment in AD symptoms with an acceptable safety and 
drug tolerance profile [42].
Nemolizumab
Given the pathogenesis of pruritus in AD, nemoli-
zumab – an antibody directed against the IL-31 receptor 
– gave hope for improvement in this persistent symptom.
In a phase 2 study in 264 adult patients with severe 
and moderate AD who were not treated with tGCSs, 
12 weeks of nemolizumab therapy brought a significant 
reduction in pruritus in treated patients. However, a lim-
ited number of patients enrolled in the study and a short 
evaluation period (12 weeks at the summary stage) did 
not allow the authors to draw conclusions about adverse 
effects [43]. Another phase 2b study with nemolizumab 
10 mg, 30 mg and 90 mg administered subcutaneously 
every 4 weeks with 226 patients was summarized after 
24 weeks of treatment. Nemolizumab produced a rapid 
and sustained improvement in cutaneous inflammation 
and itching with maximum efficacy seen with the 30 mg 
dose. The safety profile of nemolizumab was assessed 
as acceptable [44]. The drug has also been evaluated in 
a long-term study in 264 patients with moderate to se-
vere AD. Nemolizumab used for up to 64 weeks was ef-
fective and well tolerated. Similar responses in improve-
ment of EASI-75 score were observed in the treated and 
placebo groups. However, the pruritus was significantly 
reduced in patients treated with the active drug [45].
Fezakinumab
Fezakinumab, an anti-IL-22 antibody, was evaluated 
in a Phase 2a clinical trial in 60 patients with moderate 
to severe AD not controlled with tGCSs. The study ran 
for 20 weeks and results were summarized at week 12. 
Fezakinumab was well tolerated and provided a long-
term clinical improvement after the last drug adminis-
tration [46].
Etokimab
Etokimab, an anti-IL-33 monoclonal IgG1 antibody. 
A phase 2a study was conducted in 12 adult patients with 
moderate to severe AD. Patients received etokimab once. 
Rapid and sustained clinical improvement was observed. 
83% of patients reached EASI50, and 33% reached 
EASI75, with a reduction in peripheral blood eosinophils 
on day 29 after dosing. These results confirm the role 
of IL-33 in modulation of the inflammatory cascade in 
atopic skin and confirm the therapeutic potential of IL-33 
in the treatment of AD [47]. 
Tezepelumab 
Tezepelumab is a monoclonal antibody directed 
against thymic stromal lymphopoietin (anti-TSLP). Con-
sidering the role of TSLP in the pathogenesis of AD, this 
cytokine derived from damaged keratinocytes raises high 
hopes as a therapeutic target. Results of the Phase 2a 
study involving 113 patients with moderate to severe AD 
who used tGCSs along with the study drug were sum-
marized in weeks 12 and 16 of treatment with a subcu-
taneous dose of 280 mg of the drug administered every 
2 weeks. EASI50 was achieved by more patients treated 
with tezepelumab than with placebo. However, these dif-
ferences were not statistically significant, although an 
increase in the proportion of responders at the week 16 
of the study was observed [48].
OX40 molecule antagonists
OX40 is a costimulatory receptor on activated T cells 
(CD4). The fully human anti-OX40 monoclonal antibody 
was tested under the names KHK4083 and GBR830.
A phase 1 study evaluated the pharmacokinetics 
and immunogenicity of KHK4083 in 22 Japanese pa-
tients with moderate and severe AD [22]. The drug was 
administered at the dose of 10 mg/kg intravenously on 
days 1, 15 and 29 and patients were followed up to day 
155. Multiple intravenous infusions of KHK4083 had an 
acceptable security profile. After the end of treatment 
with KHK4083, a sustained improvement in AD symp-
toms was observed [49]. It is interesting whether these 
results can be extrapolated to the European population in 
the face of hypotheses/theories of differentiation of AD 
endotypes also in the ethnic context. GBR 830 was also 
evaluated among US patients with moderate to severe 
AD in a phase 2a study that enrolled 64 patients. More 
than 40 people received the drug on days 1 and 29, and 
in 40 cases its effect was assessed in histopathological 
preparations. Two doses of GBR 830 given 4 weeks apart 
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were well tolerated and induced resolution of tissue and 
clinical changes by day 71, confirming the therapeutic 
potential of this drug [50]. Results of studies with the 
monoclonal bodies described above refer to the second 
phase in adults. A clear limitation is the low size of study 
groups. Results of the third phase of this research may 
be expected soon. 
Agonists and antagonists of small molecules
JAK-STAT inhibitors are a group of drugs that have 
been intensely studied in AD in recent years. These drugs 
are less selective than monoclonal bodies. They block the 
activation of Janus kinases, translocating the signal to 
the cell nucleus and, consequently, the transcription of 
many pro-inflammatory cytokines. Results of research 
completed so far are promising. These drugs are mainly 
used orally or topically. 
Abrocitinib 
Abrocitinib is a selective JAK 1 inhibitor. A Phase 2b, 
randomized, double-blind, placebo-controlled (RDBPC) 
study was conducted in 267 adult patients with moder-
ate to severe AD with insufficient response or contrain-
dication to topical treatment. The results of the study, 
summarized after 12 weeks of treatment, showed that 
abrocitinib administered orally once daily was effective 
and well tolerated for short term use in adults with mod-
erate to severe atopic dermatitis. However, additional 
studies were necessary to assess the long-term efficacy 
and safety of the drug [51]. This year, the results of the 
phase III JADE study were published [52]. Three hundred 
and eighty-seven adolescent patients from 12 years of 
age and adults with moderate and severe atopic derma-
titis used the drug at the dose of 100 mg or 200 mg. 
The study is still ongoing, but results summarized after 
12 weeks of therapy showed the clinical effect of EASI75 
for both doses of the drug. Oral once daily monotherapy 
with abrocitinib was effective and well tolerated in ado-
lescents and adults with moderate to severe atopic der-
matitis [52].
Baricitinib
Baricitinib is a selective inhibitor of JAK 1 and JAK2. 
A phase 2 study, RDBPC, was conducted in 124 adult pa-
tients with moderate to severe AD. The drug at the dose 
of 4 mg and 2 mg was used orally with the possibility of 
simultaneous application of tGCSs. After 16 weeks of the 
study, a significant reduction in the severity of clinical 
symptoms of AD and an improvement in the quality of 
life was achieved. It is worth noting that improvement 
in clinical symptoms, including reduction of itching, was 
noted already in the first week of treatment in patients 
taking the drug at the dose of 4 mg. No serious adverse 
events were observed [53]. Results of the Phase III study 
have been published this year. The BREEZE-AD1 arm in-
cluded 624 patients, and the BREEZE-AD2 arm included 
615 patients with moderate and severe AD. Results of the 
study were collected after 16 weeks of treatment with 
baricitinib at doses of 1 mg, 2 mg and 4 mg. Baricitinib 
improved clinical signs and symptoms in patients with 
moderate to severe AD and produced a rapid reduction 
of pruritus. The drug’s safety profile was consistent with 
previous clinical studies with baricitinib in AD. The study 
is ongoing and new summaries of further results should 
be expected soon [54].
Upadacitinib
Upadacitinib is a selective Jak1 inhibitor. Results of 
the phase 2b study, planned for 88 weeks in adult pa-
tients with moderate and severe AD, showed a significant 
effect of the drug on the reduction of itch from day 2 of 
the therapy [55]. A parallel study involving 167 adult pa-
tients with moderate to severe AD reported drug efficacy 
assessed using the EASI and NRS (pruritus severity scale), 
IGA scales at all doses, i.e. 7.5 mg, 15 mg and 30 mg 
after 16 weeks of therapy. A dose-response relationship 
was observed for the efficacy of Spadacitinib; 30 mg 
once daily produced the greatest clinical benefit. No dose 
limiting toxicity was observed [56]. 
Tofacitinib
Tofacitinib is a non-selective JAK 1/3 inhibitor. It was 
administered orally to 6 patients with moderate and se-
vere atopic dermatitis, causing reduction of symptoms 
measured by the SCORAD scale without any adverse ef-
fects for up to 29 weeks of treatment, and it was applied 
topically in the form of 2% ointments [57, 58]. Sixty-nine 
patients with mild to moderate AD were enrolled in the 
phase 2a study. Results after 4 weeks of topical therapy 
showed a much greater clinical efficacy of the drug than 
placebo with an early onset of action (reduction of itch 
observed after 2 days of therapy) [58].
Ruxolitinib 
The efficacy and safety of ruxolitinib (RUX) cream 
(a selective JAK1 and JAK2 inhibitor) at concentrations 
ranging from 0.15% to 1.5% was assessed in randomized, 
controlled phase 2 clinical trials of 307 adult patients 
with mild to moderate AD. Pruritus disappeared rapidly 
within 36 h of treatment, quality of life improved with 
a good drug tolerance [59].
Delgocitinib
Delgocitinib is an inhibitor of JAK 1,2,3 and TYK2. Re-
sults of the phase III study in 158 Japanese patients from 
16 years of age with moderate to severe AD are avail-
able. 0.5% delgocitinib ointment used over a period of 
28 weeks was effective and well tolerated [60]. An earlier 
phase II study in 327 adult patients with moderate to se-
vere adult AD tested the drug at concentrations of 0.25%, 
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0.5%, 1%, 3% of the ointment applied twice a day. Results 
showed a significant and rapid improvement in objective 
clinical symptoms and pruritus severity with a favorable 
safety profile [61]. Similarly, in the phase II study conduct-
ed in a group of 103 children aged 2 to 15 years with the 
use of delgocitinib at concentrations of 0.25% and 0.5%, 
twice a day, an improvement in signs and symptoms, and 
good drug tolerance were demonstrated [62].
Cerdulatinib and gusacitinib
Cerdulatinib, a selective JAK and SYK (spleen tyrosine 
kinase) inhibitor, is currently in the phase 2 clinical trials 
using 0.4% topical gel and shows a reduction in clinical 
symptoms measured using the EASI scale [63].
Gusacitinib is another JAK/SYK kinase inhibitor in 
the phase 1b RCT. It is used at the oral dose of 20 mg, 
40 mg and 80 mg versus placebo for 4 weeks in 36 pa-
tients with moderate to severe AD. Results after 4 weeks 
of treatment showed high effectiveness and quick onset 
of action [64].
Conclusions
Presented results of studies of new monoclonal anti-
bodies and small molecules appear to be promising, but 
long-term safety and efficacy studies in larger groups of 
patients are still absent. Considering the complex etio-
pathogenesis of AD, endotypic and phenotypic differenc-
es, the prospect of having modern drugs for topical, oral 
and parental use in the therapeutic portfolio for both pe-
diatric and adult groups in the near future is encouraging. 
Currently, for the treatment of patients from 12 years 
of age with moderate to severe AD who do not respond 
to topical treatment, we recommend the use of dupil-
umab. Treatment should be initiated by physicians expe-
rienced in the diagnosis and treatment of AD.
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